Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity

被引:179
作者
Michigami, T
Shimizu, N
Williams, PJ
Niewolna, M
Dallas, SL
Mundy, GR
Yoneda, T
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol & Metab, San Antonio, TX 78284 USA
[2] Osaka Univ, Fac Dent, Dept Biochem, Suita, Osaka 565, Japan
关键词
D O I
10.1182/blood.V96.5.1953.h8001953_1953_1960
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myeloma is a unique hematologic malignancy that exclusively homes in the bone marrow and induces massive osteoclastic bone destruction presumably by producing cytokines that promote the differentiation of the hematopoietic progenitors to osteoclasts (osteoclastogenesis). It Is recognized that neighboring bone marrow stromal cells influence the expression of the malignant phenotype in myeloma cells. This study examined the role of the interactions between myeloma cells and neighboring stromal cells in the production of osteoclastogenic factors to elucidate the mechanism underlying extensive osteoclastic bone destruction. A murine myeloma cell line 5TGM1, which causes severe osteolysis, expresses alpha(4)beta(1)-integrin and tightly adheres to the mouse marrow stromal cell line ST2, which expresses the vascular cell adhesion molecule-1 (VCAM-1), a ligand for alpha(4)beta(1)-integrin. Go-cultures of 5TGM1 with primary bone marrow cells generated tartrate-resistant acid phosphatase-positive multinucleated bone-resorbing osteoclasts, Go-cultures of 5TGM1 with ST2 showed increased production of bone-resorbing activity and neutralizing antibodies against VCAM-1 or alpha(4)beta(1)-integrin inhibited this. The 5TGM1 cells contacting recombinant VCAM-1 produced increased osteoclastogenic and bone-resorbing activity. The activity was not blocked by the neutralizing antibody to known osteoclastogenic cytokines including interleukin (IL)-1, IL-6, tumor necrosis factor, or parathyroid hormone-related peptide. These data suggest that myeloma cells are responsible for producing osteoclastogenic activity and that establishment of direct contact with marrow stromal cells via alpha(4)beta(1)-integrin/VCAM-1 increases the production of this activity by myeloma cells, They also suggest that the presence of stromal cells may provide a microenvironment that allows exclusive colonization of myeloma cells in the bone marrow. (C) 2000 by The American Society of Hematology.
引用
收藏
页码:1953 / 1960
页数:8
相关论文
共 40 条
[1]   Chinese hamster ovary cells expressing α4β1 integrin stimulate osteoclast formation in vitro [J].
Akatsu, T ;
Ono, K ;
Murakami, T ;
Katayama, Y ;
Nishikawa, M ;
Wada, S ;
Yamamoto, M ;
Kugai, N ;
Matsuura, N ;
Takada, Y ;
Nagata, N .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (08) :1251-1259
[2]   Development of an in vivo model of human multiple myeloma bone disease [J].
Alsina, M ;
Boyce, B ;
Devlin, RD ;
Anderson, JL ;
Craig, F ;
Mundy, GR ;
Roodman, GD .
BLOOD, 1996, 87 (04) :1495-1501
[3]  
BARILLE S, 1995, BLOOD, V86, P3151
[4]   Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[5]  
CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688
[6]   Expression of the cell-adhesion molecule VCAM-1 by stromal cells is necessary for osteoclastogenesis [J].
Feuerbach, D ;
Feyen, JHM .
FEBS LETTERS, 1997, 402 (01) :21-24
[7]   Analysis of the activation state of alpha 4 beta 1 integrin in human B cell lines derived from myeloma, leukemia or lymphoma [J].
GarciaGila, M ;
Cabanas, C ;
GarciaPardo, A .
FEBS LETTERS, 1997, 418 (03) :337-340
[8]   A murine model of human myeloma bone disease [J].
Garrett, IR ;
Dallas, S ;
Radl, J ;
Mundy, GR .
BONE, 1997, 20 (06) :515-520
[9]   PRODUCTION OF LYMPHOTOXIN, A BONE-RESORBING CYTOKINE, BY CULTURED HUMAN MYELOMA CELLS [J].
GARRETT, IR ;
DURIE, BGM ;
NEDWIN, GE ;
GILLESPIE, A ;
BRINGMAN, T ;
SABATINI, M ;
BERTOLINI, DR ;
MUNDY, GR .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (09) :526-532
[10]   Multiple myeloma: Increasing evidence for a multistep transformation process [J].
Hallek, M ;
Bergsagel, PL ;
Anderson, KC .
BLOOD, 1998, 91 (01) :3-21